---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-108821"
form_type: "8-K"
ticker: "OGN"
cik: "0001821825"
company_name: "Organon & Co."
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:33:53.397075+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Organon Q3 revenue $1.6B, adj. EPS $1.01; FY2025 guidance lowered

## Summary
- Q3 revenue $1.602B (+1% as-reported, -1% ex-FX); net income $160M vs $359M YoY (-55%).
- GAAP diluted EPS $0.61; non-GAAP adjusted diluted EPS $1.01 (up 16% YoY).
- Adjusted EBITDA $518M (32.3% margin), up from $459M (29.0%) YoY.
- FY2025 revenue guidance cut to $6.200-6.250B; Adj EBITDA margin guidance ~31.0% (lowered).
- Nexplanon sales down 9% ex-FX due to lower U.S. government funding; Biosimilars up 19% on Hadlima.

## SEC filing metadata
- accession: 0001104659-25-108821
- form_type: 8-K
- ticker: OGN
- cik: 0001821825
- company_name: Organon & Co.
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1821825/000110465925108821/0001104659-25-108821-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1821825/000110465925108821/tm2530711d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-108821
- JSON: https://secwatch.observer/filing/0001104659-25-108821.json
- Plain text: https://secwatch.observer/filing/0001104659-25-108821.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.